甲状腺相关性眼病的评估方法及激素治疗进展  

Assessment Method of Thyroid Associated Ophthalmopathy and Its Steroid Treatment Process

作　　者：屠晓芳 张洪梅[1] 

机构地区：[1]上海交通大学医学院附属新华医院内分泌科,上海市200092

出　　处：《中国全科医学》2017年第18期2294-2298,共5页Chinese General Practice

基　　金：国家自然科学基金青年科学基金资助项目(81300642)

摘　　要：甲状腺相关性眼病(TAO)是和甲状腺疾病相关的自身免疫性疾病,常引起突眼、眼睑退缩、眼肿、复视等症状,甚至累及视神经,严重影响了患者的生活质量。糖皮质激素是其主要的治疗手段,疗效确切,但仍有相当一部分患者治疗效果不理想。目前国内外研究聚焦于TAO发病机制的探索、病情评估方法、激素治疗方案的优化、新的治疗药物的应用方面,并且取得了一定进展,本文就此做一综述,以期为个体TAO治疗方案选择提供支持,为制定TAO治疗优化方案的研究方向提供线索。Thyroid associated ophthalmopathy （TAO） is an autoimmune eye disease that associated with thyroid disease. It often causes symptoms such as exophthalmos, eyelid retraction, eye swelling, and diplopia, and even affects the optic nerve, and seriously affects the quality of life of patients. With definite curative effect, glucocorticoid is the main treatment means of TAO. However, its therapeutic outcome is unsatisfactory in a considerable number of patients. Currently domestic and foreign scholars focus on the exploration of pathogenesis, severity assessment method and optimization of steroid treatment plan and the application of novel drugs and have achieved some progresses. The review on the above aspects in this paper aims to provide support for the individual selection of therapeutic programs of TAO, and provide clues for the research direction of optimization programs of the treatment of TAO.

关 键 词：GRAVES眼病 甲状腺相关性眼病 糖皮质激素类 

分 类 号：R771.1[医药卫生—眼科]